| ORIGINAL ARTICLES |
|
|
|
|
|
Artemyrianosins A–J, cytotoxic germacrane-type sesquiterpene lactones from Artemisia myriantha |
| Xin Zhang1,2, Yun-Bao Ma1, Xiao-Feng He1, Tian-Ze Li1, Chang-An Geng1, Li-Hua Su1, Shuang Tang1, Zhen Gao1,2, Ji-Jun Chen1,2 |
1 State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, 132# Lanhei Road, Kunming, 650201, Yunnan, People's Republic of China;
2 University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China |
|
|
|
|
Abstract Ten new germacrane-type sesquiterpenoids, artemyrianosins A–J (1–10), were isolated from the aerial parts of Artemisia myriantha. Their structures were elucidated by spectral analyses including UV, IR, HRESIMS, 1D and 2D NMR, ECD and the absolute configurations of compounds 1 and 7–9 were characterized using X-ray crystallography. All isolates were tested their cytotoxicity against three human hepatoma cell lines (HepG2, Huh7, and SK-Hep-1), and compounds 1–3, 7, and 10 showed cytotoxicity with IC50 values ranging from 43.7 to 89.3 μM. Among them, the most active compound 3 exhibited activity against three human hepatoma cell lines with IC50 values of 43.7 μM (HepG2), 47.9 μM (Huh7), and 44.9 μM (SK-Hep-1).
|
| Keywords
Artemisia myriantha
Artemyrianosins A–J
Germacrane-type sesquiterpenoids
Cytotoxicity
|
| Fund:This work was supported by the Key Program of the National Natural Science Foundation of China (22137008) and the Yunnan Wanren Project (YNWR-KJLJ-2019-002). |
|
Corresponding Authors:
Ji-Jun Chen,E-mail:chenjj@mail.kib.ac.cn
E-mail: chenjj@mail.kib.ac.cn
|
|
Issue Date: 24 June 2022
|
|
|
1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mor-tality worldwide for 36 cancers in 185 countries.CA Cancer J Clin.2018;68:394-424.
2.Fattovich G, Strofolini T, Zagni I, Donato F.Hepatocellular carcinoma in cirrhosis:incidence and risk factors.Gastroenterology.2004;127:35-50.
3.Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castaneda-Orjuela CA, Catala-Lopez F, Choi JYJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, et al.Global, regional, and national cancer incidence, mortality, years ofife lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016:a systematic analysis for the global burden of disease study.JAMA Oncol.2018;4:1553-68.
4.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin.2021;71:209-49.
5.Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Len-cioni R, Koike K, ZucmanRossi J, Finn RS.Hepatocellular carcinoma.Nat Rev Dis Primers.2021;7:6.
6.Anwanwan D, Singh SK, Singh S, Saikam V, Singh R.Challenges in liver cancer and possible treatment approaches.Biochim Biophys Acta Rev Cancer.2020;1873:188314.
7.Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med.2008;359:378-90.
8.Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y.Current discovery strategies for hepatocellular carcinoma therapeutics.Expert Opin Drug Discov.2020;15:243-58.
9.Su L-H, Ma Y-B, Geng C-A, Li T-Z, Huang X-Y, Hu J, Zhang X, Tang S, Shen C, Gao Z, Zhang X-M, Chen J-J.Artematrovirenins A-P, guaiane-type ses-quiterpenoids with cytotoxicities against two hepatoma cell lines from Artemisia atrovirens.Bioorg Chem.2021;114:105072.
10.Tu Y-Y.The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine.Nat Med.2011;17:1217-20.
11.Wang S, Li J, Sun J, Zeng K-W, Cui J-R, Jiang Y, Tu P-F.NO inhibitory guaianolide-derived terpenoids from Artemisia argyi.Fitoterapia.2013;85:169-75.
12.Geng C-A, Huang X-Y, Chen X-L, Ma Y-B, Rong G-Q, Zhao Y, Zhang X-M, Chen J-J.Three new anti-HBV active constituents from the traditional Chinese herb of Yin-Chen (Artemisia scoparia).J Ethnopharmacol.2015;176:109-17.
13.Bora KS, Sharma A.The genus Artemisia:a comprehensive review.Pharm Biol.2011;49:101-9.
14.Wang J, Xu C, Wong Y-K, Li Y-J, Liao F-L, Jiang T-L, Tu Y-Y.Artemisinin, the magic drug discovered from traditional Chinese medicine.Engineering.2019;5:32-9.
15.Yao W, Wang F, Wang H.Immunomodulation of artemisinin and its derivatives.Sci Bull.2016;61:1399-406.
16.Lone SH, Bhat KA, Khuroo MA.Arglabin:from isolation to antitumor evaluation.Chem Biol Interact.2015;240:180-98.
17.Lee SH, Lee MY, Kang HM, Han DC, Son KH, Yang DC, Sung ND, Lee CW, Kim HM, Kwon BM.Anti-tumor activity of the farnesyl-protein transferase inhibitors arteminolides, isolated from Artemisa.Bioorg Med Chem.2003;11:4545-9.
18.Su L-H, Zhang X-T, Ma Y-B, Geng C-A, Huang X-Y, Hu J, Li T-Z, Tang S, Shen C, Gao Z, Zhang X-M, Chen J-J.New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity.Acta Pharm Sin B.2021;11:1648-66.
19.Su L-H, Li T-Z, Ma Y-B, Geng C-A, Huang X-Y, Zhang X, Gao Z, Chen J-J.Artematrovirenolides A-D and Artematrolides S-Z, Sesquiterpenoid dimers with cytotoxicity against three hepatoma cell lines from Artemisia atrovirens.Chin J Chem.2022;40:104-14.
20.Su L-H, Li T-Z, Geng C-A, Ma Y-B, Huang X-Y, Wang J-P, Zhang X-M, Chen J-J.Trimeric and dimeric sesquiterpenoids from Artemisia atrovirens and their cytotoxicities.Org Chem Front.2021;8:1249-56.
21.Su L-H, Geng C-A, Li T-Z, Ma Y-B, Huang X-Y, Zhang X-M, Chen J-J.Artatro-virenols A and B:Two cagelike sesquiterpenoids from Artemisia atrovirens.J Org Chem.2020;85:13466-71.
22.Zhang X-T, Hu J, Su L-H, Geng C-A, Chen J-J.Artematrolide A inhibited cervical cancer cell proliferation via ROS/ERK/mTOR pathway and meta-bolic shift.Phytomedicine.2021;91:153707.
23.Li T-Z, Yang X-T, Wang J-P, Geng C-A, Ma Y-B, Su L-H, Zhang X-M, Chen J-J.Biomimetic synthesis of lavandiolides H, I, and K and Artematrolide F via diels-alder reaction.Org Lett.2021;23:8380-4.
24.Zan K, Chen X-Q, Zhao M-B, Jiang Y, Tu P-F.Cytotoxic sesquiterpene lactones from Artemisia myriantha.Phytochem Lett.2020;37:33-6.
25.Tang S, Zhang X-T, Ma Y-B, Huang X-Y, Geng C-A, Li T-Z, Zhang X-M, Shen C, Su L-H, Gao Z, Chen J-J.Artemyrianolides A-S, Cytotoxic Sesquiterpe-noids from Artemisia myriantha.J Nat Prod.2020;83:2618-30.
26.Zan K, Chen X-Q, Zhao M-B, Tu P-F.Sesquiterpenoids from aerial parts of Artemisia myriantha.China J Chin Mater Med.2016;41:2833-7.
27.Zan K, Chen X-Q, Tu P-F.Guaianolides from aerial parts of Artemisia myriantha.China J Chin Mater Med.2018;43:2295-9. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
